Overview
Yu-jun Dong practices in Beijing, China. Mr. Dong is rated as an Experienced expert by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Castleman Disease, Lymphoid Hyperplasia, Graft Versus Host Disease (GvHD), Dysembryoplastic Neuroepithelial Tumors (DNET), and Bone Marrow Transplant.
His clinical research consists of co-authoring 67 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Dysembryoplastic Neuroepithelial Tumors (DNET).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Bone Marrow TransplantMr. Dong isAdvanced. Learn about Bone Marrow Transplant.
- Castleman DiseaseMr. Dong isAdvanced. Learn about Castleman Disease.
- Graft Versus Host Disease (GvHD)
- Lymphoid HyperplasiaMr. Dong isAdvanced. Learn about Lymphoid Hyperplasia.
- Experienced
- Acute Myeloid Leukemia (AML)Mr. Dong isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Anaplastic Large Cell LymphomaMr. Dong isExperienced. Learn about Anaplastic Large Cell Lymphoma.
- Autoimmune Hemolytic AnemiaMr. Dong isExperienced. Learn about Autoimmune Hemolytic Anemia.
- B-Cell LymphomaMr. Dong isExperienced. Learn about B-Cell Lymphoma.
- Chronic Graft Versus Host Disease (cGvHD)
- Chronic Myelomonocytic Leukemia (CMML)